Tokyo, Oct. 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059583) titled 'Alectinib and Local Therapy for Optimal Treatment in ALK-Positive non-small cell lung cancer (ALTHEO Study)' on Oct. 30.
Study Type:
Observational
Primary Sponsor:
Institute - Specified Nonprofit Corporation North East Japan Study Group
Condition:
Condition - ALK fusion gene-positive lung cancer.
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - This study aims to elucidate the clinical significance of performing local treatment for brain metastases before systemic therapy in patients with ALK-positive lung cancer with brain metastases.
Basic objectives2 - Safe...